Demichelis, Francesca
 Distribuzione geografica
Continente #
NA - Nord America 9.741
EU - Europa 1.544
AS - Asia 382
SA - Sud America 8
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 5
Totale 11.687
Nazione #
US - Stati Uniti d'America 9.732
IT - Italia 337
SE - Svezia 296
UA - Ucraina 256
FI - Finlandia 213
GB - Regno Unito 206
CN - Cina 192
DE - Germania 100
VN - Vietnam 77
BG - Bulgaria 58
JO - Giordania 26
SG - Singapore 26
LU - Lussemburgo 22
IN - India 15
TR - Turchia 15
HK - Hong Kong 12
RU - Federazione Russa 10
CA - Canada 8
AT - Austria 7
ES - Italia 5
IR - Iran 5
JP - Giappone 5
NL - Olanda 5
RO - Romania 5
A2 - ???statistics.table.value.countryCode.A2??? 4
CL - Cile 4
PL - Polonia 4
AU - Australia 3
BR - Brasile 3
EU - Europa 3
FR - Francia 3
NO - Norvegia 3
AE - Emirati Arabi Uniti 2
IL - Israele 2
KR - Corea 2
NZ - Nuova Zelanda 2
RS - Serbia 2
AM - Armenia 1
AR - Argentina 1
BA - Bosnia-Erzegovina 1
BE - Belgio 1
CH - Svizzera 1
CR - Costa Rica 1
CZ - Repubblica Ceca 1
EE - Estonia 1
GR - Grecia 1
HR - Croazia 1
IE - Irlanda 1
LK - Sri Lanka 1
MC - Monaco 1
ME - Montenegro 1
MK - Macedonia 1
PT - Portogallo 1
UZ - Uzbekistan 1
Totale 11.687
Città #
Fairfield 1.720
Chandler 956
Ashburn 836
Woodbridge 790
Seattle 695
Houston 623
Jacksonville 610
Cambridge 586
Wilmington 558
San Mateo 334
Ann Arbor 326
Princeton 226
Beijing 120
Trento 118
San Diego 108
Helsinki 103
New York 89
Dearborn 79
London 73
Lawrence 70
Boardman 69
Sofia 58
Como 56
Los Angeles 54
Dong Ket 50
Falls Church 40
Bremen 34
Norwalk 27
San Paolo di Civitate 27
Tolentino 23
Hesperange 22
Altamura 21
Des Moines 21
Bend 20
Washington 17
Kilburn 16
Düsseldorf 15
Izmir 15
Andover 13
Hong Kong 12
Hefei 11
Bonndorf 10
Kunming 10
Chiswick 9
Phoenix 9
Acton 8
Bassano del Grappa 8
Nanjing 8
New Bedfont 8
Riva Del Garda 8
Toronto 8
Wandsworth 8
Vienna 7
Chicago 6
Civitanova Marche 6
Prescot 6
Bolzano 5
Dormagen 5
Pune 5
Tappahannock 5
Guangzhou 4
Hounslow 4
Laurel 4
Lavis 4
Mountain View 4
Redmond 4
Southwark 4
Zhengzhou 4
Bovolone 3
Fuzhou 3
Hebei 3
Lappeenranta 3
Rome 3
San Michele All'adige 3
Shanghai 3
Singapore 3
Tokai 3
Turin 3
Anaheim 2
Asolo 2
Atlanta 2
Auckland 2
Augusta 2
Berlin 2
Brisbane 2
Bristol 2
Brunico 2
Castello Molina di Fiemme 2
Chapel Hill 2
Clearwater 2
Costa Mesa 2
Dallas 2
Falkenstein 2
Fremont 2
Hangzhou 2
Islington 2
Lagundo 2
Madrid 2
Milan 2
Nanchang 2
Totale 9.886
Nome #
Hit and go CAS9 delivered through a lentiviral based self-limiting circuit 246
Inherited determinants of early recurrent somatic mutations in prostate cancer 235
EthSEQ: ethnicity annotation from whole exome sequencing data 187
A highly specific SpCas9 variant is identified by in vivo screening in yeast 162
ASEQ: Fast allele-specific studies from next-generation sequencing data 144
Personalized in vitro and in vivo cancer models to guide precision medicine 142
Patient derived organoids to model rare prostate cancer phenotypes 142
Second Generation Imaging of Nuclear/Cytoplasmic HIV-1 Complexes. 137
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study 136
Ultrasensitive detection of cancer biomarkers by nickel-based isolation of polydisperse extracellular vesicles from blood 130
Genomic correlates of clinical outcome in advanced prostate cancer 128
N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer 122
A novel brain tumour model in zebrafish reveals the role of YAP activation in MAPK- and PI3K-induced malignant growth 122
High-throughput sequencing of two populations of extracellular vesicles provides an mRNA signature that can be detected in the circulation of breast cancer patients 119
TPES: Tumor Purity Estimation from SNVs 113
Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer 109
SOX2 promotes lineage plasticity and antiandrogen resistance in TP53-and RB1-deficient prostate cancer 107
A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers 107
Molecular sampling of prostate cancer: a dilemma for predicting disease progression. 106
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer 106
Defining order and timing of mutations during cancer progression: The TO-DAG probabilistic graphical model 105
Genomic correlates to the newly proposed grading prognostic groups for prostate cancer 103
RB1 heterogeneity in advanced metastatic castration-resistant prostate cancer 103
The Molecular Taxonomy of Primary Prostate Cancer 100
In-silico identification and functional validation of allele-dependent AR enhancers 100
N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. 98
Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer 98
Analysis of user-satisfaction with the use of a teleconsultation system in oncology. 97
Punctuated evolution of prostate cancer genomes. 96
Variants at IRX4 as prostate cancer expression quantitative trait loci. 96
Ancestry-specific predisposing germline variants in cancer 96
Testing mutual exclusivity of ETS rearranged prostate cancer. 95
An automated procedure to properly handle digital images in large scale tissue microarray experiments. 94
Role of non-coding sequence variants in cancer 94
An evaluation of the use of and user satisfaction with a teleconsultation system in oncology practice. 93
A Comparative Study of ERG Status Assessment on DNA, mRNA, and Protein Levels Using Unique Samples from a Swedish Biopsy Cohort. 93
Nine-gene molecular signature is not associated with prostate cancer death in a watchful waiting cohort. 92
Genome-wide linkage analysis of TMPRSS2-ERG fusion in familial prostate cancer. 92
SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer. 91
JAGGED1 expression is associated with prostate cancer metastasis and recurrence. 90
Oncogene-mediated alterations in chromatin conformation 90
Clonal evolution of chemotherapy-resistant urothelial carcinoma 90
PaCBAM: Fast and scalable processing of whole exome and targeted sequencing data 90
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. 89
User attitudes in analyzing digital slides in a quality control test bed: a preliminary study. 88
Caveolin-1 interacts with a lipid raft-associated population of fatty acid synthase. 88
Tumor clone dynamics in lethal prostate cancer 88
Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer. 87
A step toward functionally characterized prostate cancer molecular subtypes. 87
Automated immunofluorescence analysis defines microvessel area as a prognostic parameter in clear cell renal cell cancer. 87
The virtual case: a new method to completely digitize cytological and histological slides. 87
Plasma AR and abiraterone-resistant prostate cancer 87
Development and validation of a whole-exome sequencing test for simultaneous detection of point mutations, indels and copy-number alterations for precision cancer care 87
The genomic complexity of primary human prostate cancer. 86
TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications. 85
Optimizing copy number variation analysis using genome-wide short sequence oligonucleotide arrays. 85
Recurrent prostate cancer genomic alterations predict response to brachytherapy treatment 85
Integrative clinical genomics of advanced prostate cancer 85
Robotic telepathology for intraoperative remote diagnosis using a still-imaging-based system. 85
Core Biopsies from Prostate Cancer Patients in Active Surveillance Protocols Harbor PTEN and MYC Alterations 85
TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. 84
Large Oncosomes in Human Prostate Cancer Tissues and in the Circulation of Mice with Metastatic Disease 84
PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer 84
Large oncosomes mediate intercellular transfer of functional microRNA. 83
Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover. 83
TMABoost: an integrated system for comprehensive management of tissue microarray data. 82
Association of cytokeratin 7 and 19 expression with genomic stability and favorable prognosis in clear cell renal cell cancer. 82
EML4-ALK fusion lung cancer: a rare acquired event. 81
ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression. 81
Digital Pathology: Science Fiction? 81
Epigenetic Repression of miR-31 Disrupts Androgen Receptor Homeostasis and Contributes to Prostate Cancer Progression 81
ERG rearrangement metastasis patterns in locally advanced prostate cancer. 80
Recurrent gene fusions in prostate cancer 80
Exome sequencing of African-American prostate cancer reveals loss-of-function ERF mutations 80
Design and initial implementation of a regional tele-oncology project. 79
Antibody-based detection of ERG rearrangement-positive prostate cancer. 78
The landscape of somatic copy-number alteration across human cancers. 78
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. 78
Genetic variation of genes involved in dihydrotestosterone metabolism and the risk of prostate cancer. 78
Skp2 expression is associated with high risk and elevated Ki67 expression in gastrointestinal stromal tumours. 78
Unraveling the clonal hierarchy of somatic genomic aberrations 78
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. 78
Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets 77
Digital storage of glass slides for quality assurance in histopathology and cytopathology. 77
Molecular genetics of prostate cancer: Emerging appreciation of genetic complexity 77
Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation 77
Genetic predisposition to prostate cancer: Update and future perspectives 77
The lethal clone in prostate cancer: redefining the index 77
Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk 77
M-CAM expression as marker of poor prognosis in epithelial ovarian cancer. 77
Integrative microarray analysis of pathways dysregulated in metastatic prostate cancer. 77
SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines. 77
A computational framework discovers new copy number variants with functional importance. 76
Molecular archeology: unearthing androgen-induced structural rearrangements in prostate cancer genomes. 75
V-ets erythroblastosis virus E26 oncogene homolog (avian)/Trefoil factor 3/high-molecular-weight cytokeratin triple immunostain: a novel tissue-based biomarker in prostate cancer with potential clinical application. 74
TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. 74
Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease. 74
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer 74
Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. 73
Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model. 73
Totale 9.601
Categoria #
all - tutte 56.502
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 408
selected - selezionate 0
volume - volumi 200
Totale 57.110


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019789 0 0 0 0 0 0 0 0 0 0 422 367
2019/20202.899 166 130 211 305 316 203 339 280 432 249 108 160
2020/20212.590 40 357 159 330 265 182 151 162 161 230 282 271
2021/20222.157 249 327 14 92 36 81 83 390 137 212 181 355
2022/20232.024 267 235 13 328 210 316 30 145 252 34 122 72
2023/2024720 49 77 67 28 76 177 45 92 10 80 19 0
Totale 11.979